Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. - Wikidata - awgldk - TriplyDB

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

http://www.wikidata.org/entity/Q33330958

about

Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?Summary of worldwide pediatric malignancies reported after exposure to etanercept.Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease Management of psoriasis in adolescence.Etanercept in the treatment of plaque psoriasis The development and assessment of biological treatments for children.A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors.2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan Systemic arthritis in children: a review of clinical presentation and treatment Rates of malignancy associated with juvenile idiopathic arthritis and its treatment Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities.Etanercept treatment in juvenile idiopathic arthritis: the Polish registry Pain experience in children with juvenile idiopathic arthritis treated with anti-TNF agents compared to non-biologic standard treatment.Intra-articular vs. systemic administration of etanercept in antigen-induced arthritis in the temporomandibular joint. Part II: mandibular growth Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis Challenges in the management of juvenile idiopathic arthritis with etanercept Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.Pediatric psoriasis: an update.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept Systemic JIA: new developments in the understanding of the pathophysiology and therapy.A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.Treatment strategies for juvenile idiopathic arthritis.Clinical utility of etanercept in the treatment of arthritides in children and adolescents.Biologics in children's autoimmune disorders: efficacy and safety.Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?The safety profile of biologic therapies for juvenile idiopathic arthritis.Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy.

P2860

Q26739150-434C1BC8-BE7C-440B-B433-E11D7ECA3B3B Q26741357-995A27E0-98A8-4AF5-AA71-33BA8FD963C9 Q28078134-42B32A4F-725C-49AA-8498-70F9C1A0BB39 Q31032345-7AC15463-899E-437B-88D0-82FD8CAF47E5 Q33659233-3ACE1258-5172-40C9-8A44-273BA1805383 Q33765738-398FBB06-B375-400E-99D4-90017C1F5590 Q33998050-17868D9D-84A1-4BC6-A0F7-1E0B2CFEB6D9 Q34268298-0F3BB9FA-7422-45D1-AFA6-017FC807BCCD Q34415058-849E7109-31D8-43B9-ADCB-0E38D4BAE5AE Q34620263-A47DE300-A69E-472C-BE35-5C66EF67171E Q35135936-D90EB0E2-915E-4E0C-822D-12F2D2CB99D0 Q35152199-B6EE76AF-0360-47CB-9D1E-B2FC94CF52D2 Q35567870-371E15AD-B8F3-4E7C-A0BE-739A01C0DC4E Q35654296-ABE03562-767A-4121-8A1D-59BDAEFF55CA Q35659928-21D6BFAE-A91D-4851-9672-4F2B92E384BB Q35861269-366BBD08-F36D-4D5C-87C6-7387F2B386DD Q35870808-4C364666-7648-4D4C-8245-01FBE1897980 Q35926593-50B4A6E1-200D-418D-86B0-E548DAA2872C Q36131029-F29F522C-43E4-4CEF-885B-C4EAC751A7F1 Q36183846-5C533FFF-E47A-4BDE-A72C-C3590A11291F Q36552806-068CEBD2-EF15-48E0-B3B5-EE547375DF51 Q36771435-7818E625-76ED-4DE1-A611-C6BF3BC4C764 Q36843390-265221FC-4BC4-4C78-958C-EF5F83178F22 Q37133640-D9506239-D860-4472-9088-E1F0F10FB7F8 Q37177593-C1EF081E-804D-4771-A81D-35B6E5D36373 Q37207120-80ABD845-CEFA-4627-8F0F-3F01F4475CC7 Q37303219-DD330DA7-CB2A-4FC7-BB8A-B3ED1395B2C3 Q37320554-FDF02928-8EE0-4C14-8D31-B179B66EB664 Q37412966-6D1D89E1-20EC-4601-A41C-4BE8C2E563AE Q37463702-F119842F-6F8E-4568-AE1A-E556E4478C5A Q37518319-96324E2F-288C-4C8B-A666-95533249E078 Q37620829-9647D3BA-D41A-4434-911F-C420BAC431EF Q37627929-742A9972-7341-4E09-B6BF-2EF6142AB944 Q37642763-9DE7601A-AB66-4B92-9830-043FE90C45FF Q37676020-3FEF27CD-7F87-4369-91B4-A1281C986A53 Q37765830-28698A03-DE5B-4F84-8444-B2061AC1179C Q37778738-54FBDF20-0325-4CA5-A5B3-8646D5879C90 Q37780300-1397A09E-6CC7-4AB6-923C-EF04818FA64A Q37784384-92A92E7D-D6D5-4BCC-95B4-5A14DDA46687 Q37845682-E6F42C1D-CC29-45DF-80A5-7BA4628730DB

P2860

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

http://www.wikidata.org/entity/Q33330958

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Safety and efficacy of up to e ...... juvenile rheumatoid arthritis.

@ast

Safety and efficacy of up to e ...... juvenile rheumatoid arthritis.

@en

Safety and efficacy of up to e ...... juvenile rheumatoid arthritis.

@nl

type

label

Safety and efficacy of up to e ...... juvenile rheumatoid arthritis.

@ast

Safety and efficacy of up to e ...... juvenile rheumatoid arthritis.

@en

Safety and efficacy of up to e ...... juvenile rheumatoid arthritis.

@nl

prefLabel

Safety and efficacy of up to e ...... juvenile rheumatoid arthritis.

@ast

Safety and efficacy of up to e ...... juvenile rheumatoid arthritis.

@en

Safety and efficacy of up to e ...... juvenile rheumatoid arthritis.

@nl

P1433

Q33330958-7767271F-50D1-4A14-A41D-982D8CFAD596

P1476

Q33330958-C133D58C-68F5-4C45-AF51-10A5028DD8ED

P2093

Q33330958-119418D4-45F8-40E4-A430-CC8B6ABCF6C4

Q33330958-279E006E-30FF-49DA-8C02-022996178A98

Q33330958-4EF592C4-6842-4B52-9FDB-BE8757DAF80F

Q33330958-BD9C518C-C997-44E9-86C3-CD33E4957587

Q33330958-D7DDBACD-AD0C-45BA-8844-BBED60F01697

Q33330958-EC34229B-008A-4EBF-9DFA-5945AF3FF0BD

Q33330958-EFA26F8B-3AC2-46FF-9257-B8B7C5AC9E31

Q33330958-FE6F2B3D-D159-4EB5-9274-00191217B0E4

P304

Q33330958-853B88C1-2267-459C-B207-D7A828970E9A

P31

Q33330958-7E62A02D-CC8E-45E6-BF34-687AD5702307

P356

Q33330958-D2A26CFC-B27C-4DF9-8FBD-E6FDAA56804D

P433

Q33330958-AE8C42C3-ABC9-45C9-8234-C7BAEA92820D

P478

Q33330958-B0E61108-FD09-4E88-8F1D-C677DC8CB0FF

P50

Q33330958-3767494F-3683-4CCE-A118-893FB9DD121C

P577

Q33330958-13A8BCA5-93E3-47E5-9390-13762E1A9B55

P5875

Q33330958-F92EC2F3-78EE-45CF-87C4-BAA7307B6B42

P698

Q33330958-422CF7F5-8C3F-46D2-925B-C408CE1078A9

P921

Q33330958-086F3896-AA64-4142-9DBD-AD10B94E5B14

P356

P1433

Arthritis & Rheumatology

P1476

Safety and efficacy of up to e ...... juvenile rheumatoid arthritis.

@en

P2093

Andreas Reiff

http://www.w3.org/2001/XMLSchema#string

Carol A Wallace

http://www.w3.org/2001/XMLSchema#string

Daniel J Lovell

http://www.w3.org/2001/XMLSchema#string

Edward H Giannini

http://www.w3.org/2001/XMLSchema#string

Pediatric Rheumatology Collaborative Study Group

http://www.w3.org/2001/XMLSchema#string

Scott W Baumgartner

http://www.w3.org/2001/XMLSchema#string

Shao-Lee Lin

http://www.w3.org/2001/XMLSchema#string

Yun Chon

http://www.w3.org/2001/XMLSchema#string

P304

1496-1504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.23427

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Norman T Ilowite

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5413822

http://www.w3.org/2001/XMLSchema#string

P698

18438876

http://www.w3.org/2001/XMLSchema#string

P921